- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Oral Berotralstat as effective as intravenous agents for long-term prophylaxis of hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic condition that causes swelling under the skin and lining of the gut and lungs. It can happen in different parts of our body. Berotralstat, a first-line, once-daily oral plasma kallikrein inhibitor for long-term prophylaxis of HAE, is an effective and well-tolerated treatment option.
A study report summarizes the safety, effectiveness, and impact on treatment satisfaction in patients who switched from injectable long-term prophylactics (LTPs) to oral berotralstat monotherapy (150 mg daily) at US sites in the international open-label APeX-S study. The study is published in Annals of Allergy, Asthma & Immunology.
The study finds that injectable prophylactic medication to berotralstat was safe and tolerable. Patients switching to berotralstat monotherapy maintained good control of their HAE symptoms and reported improved treatment satisfaction.
Researchers in APeX-S (ClinicalTrials.gov, NCT03472040) an open-label Phase 2 study of berotralstat conducted in 22 countries. They focused on APeX-S patients enrolled at US sites who switched from injectable LTPs to berotralstat 150 mg once-daily monotherapy.
The key findings of the study are
• Thirty-four patients discontinued lanadelumab (n = 21), subcutaneous C1 esterase inhibitor (n = 11), or intravenous C1 esterase inhibitor (n = 2) and switched to berotralstat 150 mg monotherapy.
• Vomiting, diarrhea, and upper respiratory tract infection were the most common adverse events (each 11.8%). Mean monthly attack rates were consistently low following the switch to berotralstat.
• The mean (standard error of the mean) monthly attack rate was 0.29 (0.11) at Month 1, 0.48 (0.15) at Month 6, and 0.58 (0.23) at Month 12. The median attack rate was 0 attacks/month throughout 12 months of treatment.
• Improvements were observed in the Treatment Satisfaction Questionnaire for Medication from baseline to Month 12 following the switch to berotralstat monotherapy, with the greatest improvements in convenience.
Researchers concluded that “The transition from injectable prophylactic medication to berotralstat was generally well tolerated. Patients switching to berotralstat monotherapy maintained good control of their HAE symptoms and reported improved treatment satisfaction.”
Reference: Marc A. Riedl MD MS, Daniel Soteres MD, J. Wesley Sublett MD; Hereditary angioedema outcomes in US patients switched from injectable long-term prophylactic medication to oral berotralstat; Annals of Allergy, Asthma & Immunology; DOI: https://doi.org/10.1016/j.anai.2023.11.016.
MSc. Neuroscience
Niveditha Subramani a MSc. Neuroscience (Faculty of Medicine) graduate from University of Madras, Chennai. Ambitious in Neuro research having worked in motor diseases and neuron apoptosis is interested in more of new upcoming research and their advancement in field of medicine. She has an engrossed skill towards writing and her roles at Medical dialogue include Sr. Content writer. Her news covers new discoveries and updates in field of medicine. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751